Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb; and PF'4404, from the partnership between Pfizer and 3SBio.
May 21, 2026 05:00 PM EDT
New data show VEGF bispecifics could compete with Summit, Akeso drug
Max Gelman
Much of the attention heading into the annual ASCO meeting next week has focused on Summit Therapeutics and Akeso’s plenary presentation for their bispecific drug …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
All of the regular ASCO abstracts dropped Thursday afternoon. Find updates on potential successors for Pfizer’s blockbuster…
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga | Two months after UCB revealed the success of…
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
Drugmakers are exploring a variety of approaches to treat head and neck cancers, from bispecific antibodies that target both PD-1…
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
